Mesalamine 800 tablet
Description
MESROOT-800
Mesalamine Delayed Release 800 mg Tablets
Division: DIABGLYM
Composition
Each delayed-release tablet contains:
Mesalamine IP — 800 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Delayed-release oral tablet
Product Description
MESROOT-800 contains Mesalamine Delayed Release 800 mg, an advanced anti-inflammatory aminosalicylate formulation designed for the treatment and maintenance of remission in ulcerative colitis and other inflammatory bowel diseases (IBD). The delayed-release formulation ensures targeted drug delivery to the colon, where Mesalamine exerts its local anti-inflammatory action on the intestinal mucosa.
Mesalamine is widely prescribed by gastroenterologists for patients with mild to moderate ulcerative colitis, proctosigmoiditis, pancolitis, and long-term maintenance therapy to reduce disease relapse. It helps decrease intestinal inflammation, improve mucosal healing, reduce rectal bleeding and diarrhea, and maintain long-term remission in patients with inflammatory bowel disease.
MESROOT-800 is particularly beneficial for patients requiring targeted colonic drug delivery, maintenance of ulcerative colitis remission, long-term mucosal protection, and effective anti-inflammatory therapy with minimal systemic absorption.
Technical Knowledge of Mesalamine Delayed Release
Mesalamine (5-aminosalicylic acid) acts locally within the intestinal mucosa by inhibiting cyclooxygenase and lipoxygenase pathways, reducing the synthesis of inflammatory prostaglandins and leukotrienes. It also modulates cytokine production, inhibits nuclear factor-kappa B (NF-kB) activation, reduces oxidative stress, and suppresses inflammatory cell migration within the colon.
The delayed-release tablet is formulated with pH-dependent coating technology that protects the drug from release in the stomach and proximal small intestine, allowing targeted release in the terminal ileum and colon, where inflammation is most prominent in ulcerative colitis.
Mechanism of Action
Mesalamine inhibits cyclooxygenase and lipoxygenase pathways, reduces prostaglandin and leukotriene synthesis, suppresses inflammatory cytokines, decreases oxidative stress, promotes mucosal healing, and reduces intestinal inflammation through local colonic action.
Key Benefits
Targets inflammation directly in the colon
Promotes mucosal healing
Helps induce and maintain remission in ulcerative colitis
Reduces rectal bleeding and diarrhea
Provides targeted delayed-release colonic delivery
Minimizes systemic drug exposure
Supports long-term inflammatory bowel disease management
Suitable for long-term therapy under medical supervision
Clinical Applications
MESROOT-800 is commonly prescribed for mild to moderate ulcerative colitis, extensive ulcerative colitis, pancolitis, proctosigmoiditis, maintenance of ulcerative colitis remission, inflammatory bowel disease, and long-term colonic anti-inflammatory therapy.
Facts About Mesalamine
Mesalamine is considered first-line therapy for mild to moderate ulcerative colitis and maintenance of remission. Delayed-release formulations are specifically designed to deliver the drug to the colon, improving therapeutic efficacy while minimizing systemic adverse effects. Long-term Mesalamine therapy has demonstrated significant benefits in maintaining remission, promoting mucosal healing, reducing disease relapse, and improving quality of life in patients with ulcerative colitis.
Key Facts
Delayed-release aminosalicylate therapy
Mesalamine 800 mg for targeted colonic anti-inflammatory treatment
Promotes mucosal healing and remission maintenance
Effective in ulcerative colitis and inflammatory bowel disease
Minimizes systemic drug exposure
Evidence-based gastroenterology therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
MESROOT-800 is an excellent product for PCD Pharma Franchise, Gastroenterology Franchise, and Specialty Pharma Franchise across India. The increasing prevalence of ulcerative colitis, inflammatory bowel disease, gastrointestinal inflammatory disorders, and long-term maintenance therapy creates strong prescription demand and excellent market potential for this formulation.
Why Choose MESROOT-800 for PCD Pharma Franchise?
High prescription potential
Strong gastroenterologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and specialty marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Mesalamine Delayed Release 800 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and specialty gastroenterology businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented delayed-release formulation
Advanced pH-dependent coating technology
Blister and Alu-Alu packaging options
MESROOT-800 from DIABGLYM combines targeted colonic anti-inflammatory therapy, mucosal healing support, evidence-based ulcerative colitis management, and high-quality pharmaceutical manufacturing, making it an ideal product for gastroenterologists, physicians, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Mesalamine delayed-release formulation.
